Journal of Nuclear Medicine and Molecular Imaging
Pretreatment 18 F-FDG uptake heterogeneity predicts response to CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer
By Mengjing Ji, Guang Ma, Shuting Li and 4 others.
Abstract
Background
Intratumoral heterogeneity in 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake has been shown to serve as an alternative biomarker for predicting treatment outcomes across various tumors. This study aims to explore the potential value of 18 F-FDG uptake heterogeneity in predicting the efficacy of cyclin-dependent kinases 4/6 (CDK4/6) inhibitor therapy for metastatic hormone receptor-positive breast cancer (MHBC).